New malaria vaccine will save children's lives
One of the nastiest side-effects of COVID-19 was malaria. The pandemic caused major disruptions to anti-malaria projects across Africa, and a significant rise in the number of cases and deaths — most of which were in children under the age of 5.
What's new: Now there's real hope that a vaccine could cause deaths to plunge.
Why it matters: The R21 vaccine, developed by the University of Oxford, has already been approved by both Ghana and Nigeria; it's an improved version of the RTS,S vaccine that has already been approved by the WHO.
- The Serum Institute of India expects to produce as many as 200 million doses per year, and is building a vaccine factory in Ghana's capital, Accra.
- The vaccine is intended for use in children between 5 months and 3 years old, and early indications are that it is 77% effective.
The bottom line: "This is a preventable, treatable disease," says Harvard professor Dyann Wirth. "No child should die of this."